Treatment of resistance to Fam-trastuzumab deruxtecan-nxki

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is a drug used to treat HER2-positive breast cancer,HER2-mutated non-small cell lung cancer, and gastric cancer. Although detrastuzumab is effective in many patients, some patients may develop resistance.

If a patient develops resistance to trastuzumab, increasing the dose of trastuzumab may help to overcome resistance in some cases. Doctors can decide whether this method is suitable based on the patient's specific circumstances. Combining trastuzumab with other drugs may be an effective resistance management strategy. For example, combining it with chemotherapy drugs or other targeted therapies may be able to enhance the effectiveness of treatment and reduce the development of drug resistance. Neratinib (Neratinib) is an oral irreversible panHER inhibitor. Preclinical data in breast cancer cell lines indicate that it can overcome primary and acquired trastuzumab resistance in HER2-positive breast cancer cell lines. However, everyone’s physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

Trastuzumab is a new type of injectable anti-cancer drug. The original drug has been launched in China, but it has not yet entered the scope of medical insurance. It is a strictly controlled drug. The domestic price is not yet clear, and its purchase method is difficult. The Hong Kong version of TrastuzumabSpecifications100mg may cost more than 10,000 yuan per box, and the Hong Kong original versionTrastuzumabOriginal drug specificationsThe price of 100mg per box may be around 15,000 yuan (the price may fluctuate due to exchange rate effects). The drug ingredients of the two are basically the same. There is currently no generic drug of Trastuzumab produced and launched. For more specific prices and drug information, please consult the medical consultant of the drug.